<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MAGNESIUM SULFATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MAGNESIUM SULFATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute asthma</span>,
                <span class="indication">Continuing respiratory deterioration in anaphylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.2&#8211;2 g, to be given over 20 minutes.</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                40 mg/kg (max. per dose 2 g), to be given over 20 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of seizures in pre-eclampsia</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 4 g, to be given over 5&#8211;15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours, if seizure occurs, additional dose of 2 g by intravenous injection to be administered.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of seizures and prevention of seizure recurrence in eclampsia</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 4 g, to be given over 5&#8211;15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours after seizure or delivery (whichever is later), if seizure recurs, increase the infusion rate to 1.5&#8211;2 g/hour or give an additional dose of 2 g by intravenous injection.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Hypomagnesaemia</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Up to 40 g, dose given over up to 5 days may be required to replace the deficit (allowing for urinary losses).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Hypomagnesaemia maintenance (e.g. in intravenous nutrition)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5&#8211;5 g daily, usual dose 3 g daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Emergency treatment of serious arrhythmias</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 g, to be given over 10-15 minutes, dose may be repeated once if necessary.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Rapid bowel evacuation (acts in 2&#8211;4 hours)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;10 g, dose to be mixed in a glass of water, taken preferably before breakfast.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Magnesium sulfate heptahydrate 1&#8239;g equivalent to Mg<sup>2+</sup> approx. 4&#8239;mmol.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">When used for <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Arrhythmias</ph> or <ph outputclass="indication">Prevention of seizures in pre-eclampsia</ph> or <ph outputclass="indication">Treatment of seizures and prevention of seizure recurrence in eclampsia</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in adults</h3>
              <p>Not known to be harmful for short-term intravenous administration in eclampsia, but excessive doses in third trimester cause neonatal respiratory depression.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">When used for <ph outputclass="indication">Neonatal hypocalcaemia</ph> or <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Torsade de pointes</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in children</h3>
              <p>Sufficient amount may cross the placenta in mothers treated with high doses e.g. in pre-eclampsia, causing hypotonia and respiratory depression in newborns.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in hepatic coma if risk of renal failure.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Avoid or reduce dose.</p>
            </section>
        
            <section class="generalInformation">
              <p>Increased risk of toxicity.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Arrhythmias, coma, confusion, drowsiness, flushing of skin, hypermagnesaemia associated side-effects, hypotension, loss of tendon reflexes, muscle weakness, nausea, respiratory depression, thirst, vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> colic, diarrhoea,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, in persistent pulmonary hypertension of the newborn, dilute to a max. concentration of 100&#8239;mg/mL (10%) (0.4&#8239;mmol/ mL Mg<sup>2+</sup>) magnesium sulfate heptahydrate (200&#8239;mg/ mL (0.8&#8239;mmol/mL Mg<sup>2+</sup>) if fluid restricted) with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>In severe hypomagnesaemia administer initially via controlled infusion device (preferably syringe pump).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous injection</i>, in arrhythmias, hypomagnesaemia, eclampsia, and pre-eclampsia, give continuously in Glucose 5% or Sodium chloride 0.9%.</p><p>Concentration of magnesium sulfate heptahydrate should not exceed 20% (200&#8239;mg/mL or 0.8&#8239;mmol/mL Mg<sup>2+</sup>); dilute 1 part of magnesium sulfate injection 50% with at least 1.5 parts of water for injections.</p><p>Max. rate 150&#8239;mg/minute (0.6&#8239;mmol/minute Mg<sup>2+</sup>).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For neonatal hypocalcaemia, hypomagnaesemia, and torsade de pointes, dilute to 10% (100&#8239;mg magnesium sulfate heptahydrate (0.4&#8239;mmol Mg<sup>2+</sup>) in 1&#8239;mL) with Glucose 5% <i>or</i> 10%, Sodium Chloride 0.45% <i>or</i> 0.9% <i>or</i> Glucose and Sodium Chloride combinations. Up to 20% solution may be given in fluid restriction. Rate of administration should not exceed 10&#8239;mg/kg/minute (0.04&#8239;mmol/kg/minute Mg<sup>2+</sup>) of magnesium sulfate heptahydrate.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With oral use:</strong>
            in rapid bowel evacuation&#8212;elderly and debilitated patients in adults
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor blood pressure, respiratory rate, urinary output and for signs of overdosage (loss of patellar reflexes, weakness, nausea, sensation of warmth, flushing, drowsiness, double vision, and slurred speech).</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Unlicensed indication in severe acute asthma.</p><p>Continuing respiratory deterioration in anaphylaxis.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>The BP directs that the label states the strength as the % w/v of magnesium sulfate heptahydrate and as the approximate concentration of magnesium ions (Mg<sup>2+</sup>) in mmol/mL.</p><p>Magnesium Sulfate Injection BP is a sterile solution of Magnesium Sulfate Heptahydrate.</p>
            </section>
      </section>







      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>Magnesium sulfate is on sale to the public as Epsom Salts.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MAGNESIUM SULFATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,
            cutaneous solution,
            solution for infusion,
            capsule,
            infusion,

            <div id="PHP77835"><a href="../medicinalForm/PHP77835.html" data-target="#PHP77835" data-action="load">Solution for injection</a></div>
            <div id="PHP77825"><a href="../medicinalForm/PHP77825.html" data-target="#PHP77825" data-action="load">Solution for infusion</a></div>
            <div id="PHP77812"><a href="../medicinalForm/PHP77812.html" data-target="#PHP77812" data-action="load">Powder</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
